Review
Oncology
Sophia C. Kamran, Jason A. Efstathiou
Summary: Radiation therapy is crucial in the management of genitourinary malignancies, with technological advancements improving outcomes and reducing toxicities. Recent advances in imaging and genomic techniques can provide personalized tumor and patient information for treatment decisions. Targeted molecular therapies based on tumor biology offer individualized treatment recommendations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Steffen Ventz, Sergio Bacallado, Rifaquat Rahman, Sara Tolaney, Jonathan D. Schoenfeld, Brian M. Alexander, Lorenzo Trippa
Summary: The study highlights the importance of sharing early efficacy and toxicity results during ongoing clinical trials for physicians and patients to make informed enrollment decisions. This practice may impact various operating characteristics, trial duration, and statistical validity.
NATURE COMMUNICATIONS
(2021)
News Item
Biochemistry & Molecular Biology
Paul Webster
Summary: Cancer immunotherapy has generated significant excitement, but the potential lies in antibody-drug conjugates, proteolysis-targeting chimeras, and liquid biopsy for early detection.
Review
Oncology
Andrew Wahba, Russ Wolters, Jennifer H. Foster
Summary: Patients with high-risk neuroblastoma have a poor chance of survival and often develop significant late-effects. ALK inhibitors and anti-GD2 therapies have become mainstays of treatment, but the development of additional molecular targeted therapy has proven challenging due to the heterogeneity of high-risk neuroblastoma.
Review
Gastroenterology & Hepatology
Claudia W. K. Wu, Madeleine Reid, Simon Leedham, Rashid N. Lui
Summary: Colorectal cancer is a genetically heterogeneous disease, and its pathogenesis involves genetic and epigenetic alterations, leading to treatment challenges and high mortality rates. Molecular analysis has revealed the impact of intestinal signaling pathways on colonic epithelial cell fate and the role of the tumor microenvironment in cancer growth. Translating research knowledge into clinical practice and targeting potential drug targets may improve patient outcomes.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Genetics & Heredity
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, Razelle Kurzrock
Summary: Recent breakthroughs in biotechnology have allowed for the identification of unique molecular features that drive malignancies. Precision medicine has used next-generation sequencing and matched targeted therapy/immunotherapy to transform the outlook for fatal cancers. Multiple trial designs and personalized combination treatment strategies have been implemented to accelerate drug evaluation and individualized treatment.
Article
Medicine, General & Internal
Stefanie Hayoz, Benjamin Kasenda, Annina Lea Schenker, Christoph Kopp, Sami Schar, Beat Thurlimann, Roger von Moos, Miklos Pless
Summary: Premature trial discontinuation and non-publication of results are still major issues in cancer trials conducted by SAKK. Although SAKK has improved its trial conduct, there is still room for improvement.
Editorial Material
Biochemistry & Molecular Biology
Michael J. Grant, Sarah B. Goldberg
Summary: Innovative clinical trial designs with a patient-centered mission are crucial to advancing modern cancer care. The adaptive phase 2 umbrella study CTONG1702 provides one model for this new era of trial design.
Article
Oncology
Rema Shah, Daniel Boffa, Sajid Khan, Benjamin Judson
Summary: This study utilized publicly available data from clinicaltrials.gov to investigate the representation of surgery in non-industry-funded oncological clinical trials in the United States from 2012 to 2022. The results showed a 43.2% increase in surgical trials and an 18.9% increase in oncology trials over the past two decades. The focus of clinical trials is shifting towards encouraging innovation in more diagnostic and less invasive techniques, as well as targeted therapies.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Letter
Medicine, General & Internal
Timothee Olivier, Alyson Haslam, Vinay Prasad
Summary: This cross-sectional study investigates the commonness of restricted choice of treatment among physicians and investigators conducting oncology randomized clinical trials (RCTs) in control groups.
Article
Oncology
Jose A. Carreno Duenas, P. Natalia Sanchez, Carlos E. Bonilla
Summary: This study aimed to compare overall survival, progression-free survival, and treatment response between patients who participated in cancer clinical trials and those who refused to participate. The results showed that participants had higher rates of stable disease and complete response, and longer progression-free survival. Therefore, participation in clinical trials could improve treatment outcomes and reduce disease progression.
Article
Medicine, General & Internal
Fidel Rubagumya, Wilma M. Hopman, Bishal Gyawali, Deborah Mukherji, Nazik Hammad, C. S. Pramesh, Mykola Zubaryev, Alexandru Eniu, Audrey T. Tsunoda, Tezer Kutluk, Ajay Aggarwal, Richard Sullivan, Christopher M. Booth
Summary: A substantial proportion of randomized clinical trials (RCTs) led by high-income countries (HICs) enroll patients from lower middle-income countries (LMICs) and upper middle-income countries (UMICs), but the participation of these countries does not reflect their overall cancer research output.
Article
Oncology
Joseph M. M. Unger, Michael LeBlanc, Suzanne George, Norman Wolmark, Walter J. J. Curran Jr, Peter J. J. O'Dwyer, Mitchell D. D. Schnall, Robert S. S. Mannel, Sumithra J. J. Mandrekar, Robert J. J. Gray, Fengmin Zhao, Mariama Bah, Riha Vaidya, Charles D. D. Blanke
Summary: The National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups in the United States have conducted publicly funded oncology research for 50 years, but the combined impact of all adult network group trials has never been systematically examined.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Koren Smith, Kenneth Ulin, Michael Knopp, Stephan Kry, Ying Xiao, Mark Rosen, Jeff Michalski, Matthew Iandoli, Fran Laurie, Jean Quigley, Heather Reifler, Juan Santiago, Kathleen Briggs, Shawn Kirby, Kate Schmitter, Fred Prior, Joel Saltz, Ashish Sharma, Maryann Bishop-Jodoin, Janaki Moni, M. Giulia Cicchetti, Thomas J. FitzGerald
Summary: Clinical trials have become the key method for validating improvements in oncology clinical practice. There have been significant advancements in radiation oncology practice, including the use of advanced technology, image guidance, and artificial intelligence in treatment planning. These improvements have enhanced the quality of patient care and expanded the use of radiation therapy in primary disease settings.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Medicine, General & Internal
Elizabeth B. Lamont, Sheila S. Diamond, Ron G. Katriel, Lisa L. Ensign, Jingshu Liu, Emelly Rusli, G. Caleb Alexander
Summary: This cohort study evaluates the association between the COVID-19 pandemic and clinical research and development for cancer through studying the initiation of oncology clinical trials over time.